Immunological effic acy of a prime-boost pneumococcal vaccination in HIV-infected adults

Methods: Two-hundred and twelve patients with CD4 cell counts of 200–500 cells/ml and HIV RNA<4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n1⁄4106) or PPV alone at week 4 (n1⁄4106). The proportion of responders to 0, 1–2, 3–4, 5–7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment.